Showing results (121-130 of 376) with videos related to

Sort By:
Pageof 38
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 15, 2025
Age-standardized comparison of coronary artery disease, stroke incidence, and all-cause mortality between people living with HIV and the general population in SpainAnna Camps-Vilaró, Ramon Teira, Isaac Subirana, et al.
AIDS (London, England)|June 23, 2006
Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovirJosep M Llibre, Pere Domingo, Rosario Palacios, et al.
The Journal of Antimicrobial Chemotherapy|March 15, 2015
Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levelsEugènia Negredo, Adolfo Diez-Pérez, Anna Bonjoch, et al.
AIDS (London, England)|October 12, 2010
Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patientsPere Domingo, José M Gallego-Escuredo, Joan C Domingo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2004
Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavirEsteban Martínez, Pere Domingo, María J Galindo, et al.
Aging Cell|July 26, 2018
Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissueJoan Villarroya, José M Gallego-Escuredo, Alejando Delgado-Anglés, et al.
Antiviral Therapy|October 12, 2007
Altered expression of nucleoside transporter genes (SLC28 and SLC29) in adipose tissue from HIV-1-infected patientsJordi P Guallar, Pedro Cano-Soldado, Ivette Aymerich, et al.
Antiviral Therapy|February 2, 2012
Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudineVicens Diaz-Brito, Agathe León, Hernando Knobel, et al.
The Journal of Antimicrobial Chemotherapy|March 2, 2012
Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimenJoaquin Burgos, Manuel Crespo, Vicenç Falcó, et al.
The Lancet. Infectious Diseases|October 1, 2013
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trialFrançois Raffi, Hans Jaeger, Eugenia Quiros-Roldan, et al.
Pageof 38